Transcatheter aortic valve replacement (TAVR) using the SAPIEN 3 system (Edwards Lifesciences) showed a significantly lower rate of the primary endpoint, a composite of death, stroke, and rehospitalization at 1 year, compared with surgical valve replacement in patients with severe aortic stenosis at low surgical risk in the PARTNER 3 study.
The study is to be presented Sunday March 17 here at the American College of Cardiology 68th Annual Scientific Session (ACC) 2019 by Martin Leon, MD, Columbia University Medical Center, New York, and simultaneously published in The New England Journal of Medicine (NEJM)
The PARTNER 3 trial randomly assigned 1000 patients with severe aortic stenosis and low surgical risk to undergo either TAVR with transfemoral placement of a balloon-expandable valve (SAPIEN 3) or surgery.
The mean age was 73 years. The mean Society of Thoracic Surgeons risk score was 1.9% (with scores ranging from 0 to 100% and higher scores indicating a greater risk for death within 30 days after surgery).
The primary endpoint — a composite of death from any cause, stroke, or rehospitalization at 1 year — occurred in 8.5% of the TAVR group vs 15.1% of the surgical group, fulfilling the requirements for both noninferiority (P < .001) and superiority (P = .001) of TAVR.
medscape.com/viewarticle/910503
American College of Cardiology 68th Annual Scientific Session (ACC) 2019. To be presented March 17, 2019.
N Engl J Med. Published online March 16, 2019. Full text
